BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 32761301)

  • 1. The AKR1B1 inhibitor epalrestat suppresses the progressionĀ of cervical cancer.
    Ji J; Xu MX; Qian TY; Zhu SZ; Jiang F; Liu ZX; Xu WS; Zhou J; Xiao MB
    Mol Biol Rep; 2020 Aug; 47(8):6091-6103. PubMed ID: 32761301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gedunin, A Neem Limonoid in Combination with Epalrestat Inhibits Cancer Hallmarks by Attenuating Aldose Reductase-Driven Oncogenic Signaling in SCC131 Oral Cancer Cells.
    Tanagala KKK; Baba AB; Kowshik J; Reddy GB; Nagini S
    Anticancer Agents Med Chem; 2018; 18(14):2042-2052. PubMed ID: 30062975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldo-keto reductase inhibitors increase the anticancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia.
    Kikuya M; Furuichi K; Hirao T; Endo S; Toyooka N; Ito K; Aoki S
    J Pharmacol Sci; 2021 Sep; 147(1):1-8. PubMed ID: 34294359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy.
    Hotta N; Kawamori R; Fukuda M; Shigeta Y;
    Diabet Med; 2012 Dec; 29(12):1529-33. PubMed ID: 22507139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and biological evaluation of new epalrestat analogues as aldose reductase inhibitors (ARIs).
    Reddy TN; Ravinder M; Bagul P; Ravikanti K; Bagul C; Nanubolu JB; Srinivas K; Banerjee SK; Rao VJ
    Eur J Med Chem; 2014 Jan; 71():53-66. PubMed ID: 24275248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AKR1B1 promotes basal-like breast cancer progression by a positive feedback loop that activates the EMT program.
    Wu X; Li X; Fu Q; Cao Q; Chen X; Wang M; Yu J; Long J; Yao J; Liu H; Wang D; Liao R; Dong C
    J Exp Med; 2017 Apr; 214(4):1065-1079. PubMed ID: 28270406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Moving toward a new horizon for the aldose reductase inhibitor epalrestat to treat drug-resistant cancer.
    Bailly C
    Eur J Pharmacol; 2022 Sep; 931():175191. PubMed ID: 35964660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Inhibition effect of epalrestat on rat lens osmotic expansion].
    Ji LX; Shen N; Li CN; Liu Q; Huan Y; Shen ZF
    Yao Xue Xue Bao; 2009 Oct; 44(10):1107-11. PubMed ID: 20055132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aldo-keto reductase family 1 member B induces aortic valve calcification by activating hippo signaling in valvular interstitial cells.
    Gao C; Hu W; Liu F; Zeng Z; Zhu Q; Fan J; Chen J; Cheng S; Yu K; Qian Y; Ren T; Zhao J; Liu X; Wang J
    J Mol Cell Cardiol; 2021 Jan; 150():54-64. PubMed ID: 33045251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aldose reductase inhibitor improves insulin-mediated glucose uptake and prevents migration of human coronary artery smooth muscle cells induced by high glucose.
    Yasunari K; Kohno M; Kano H; Minami M; Yoshikawa J
    Hypertension; 2000 May; 35(5):1092-8. PubMed ID: 10818070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Corticosteroids and aldose reductase inhibitor Epalrestat modulates cardiac action potential via KvĪ²1.1 (AKR6A8) subunit of voltage-gated potassium channel.
    Tur J; Badole SL; Cheng F; Das A; Kukreja RC; Tipparaju SM
    Mol Cell Biochem; 2017 Dec; 436(1-2):71-78. PubMed ID: 28585087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ZNF521/EBF1 axis regulates AKR1B1 to promote the proliferation, migration, and invasion of gastric cancer cells.
    Cheng Y; Ni YJ; Tang LM
    Kaohsiung J Med Sci; 2023 Mar; 39(3):244-253. PubMed ID: 36397644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epalrestat, an Aldose Reductase Inhibitor Prevents Glucose-Induced Toxicity in Human Retinal Pigment Epithelial Cells In Vitro.
    Senthilkumari S; Sharmila R; Chidambaranathan G; Vanniarajan A
    J Ocul Pharmacol Ther; 2017; 33(1):34-41. PubMed ID: 27835059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted co-delivery of the aldose reductase inhibitor epalrestat and chemotherapeutic doxorubicin via a redox-sensitive prodrug approach promotes synergistic tumor suppression.
    Banala VT; Urandur S; Sharma S; Sharma M; Shukla RP; Marwaha D; Gautam S; Dwivedi M; Mishra PR
    Biomater Sci; 2019 Jun; 7(7):2889-2906. PubMed ID: 31086900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitor selectivity between aldo-keto reductase superfamily members AKR1B10 and AKR1B1: role of Trp112 (Trp111).
    Zhang L; Zhang H; Zhao Y; Li Z; Chen S; Zhai J; Chen Y; Xie W; Wang Z; Li Q; Zheng X; Hu X
    FEBS Lett; 2013 Nov; 587(22):3681-6. PubMed ID: 24100137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of lignans extracted from Eucommia ulmoides and aldose reductase inhibitor epalrestat on hypertensive vascular remodeling.
    Gu J; Wang JJ; Yan J; Cui CF; Wu WH; Li L; Wang ZS; Yu M; Gao N; Liu L; Ouyang DS
    J Ethnopharmacol; 2011 Jan; 133(1):6-13. PubMed ID: 20817083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of inhibitory activity of the aldose reductase inhibitor, epalrestat, on high glucose-mediated endothelial injury: neutrophil-endothelial cell adhesion and surface expression of endothelial adhesion molecules.
    Okayama N; Omi H; Okouchi M; Imaeda K; Kato T; Akao M; Imai S; Shimizu M; Fukutomi T; Itoh M
    J Diabetes Complications; 2002; 16(5):321-6. PubMed ID: 12200074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epalrestat: an aldose reductase inhibitor for the treatment of diabetic neuropathy.
    Ramirez MA; Borja NL
    Pharmacotherapy; 2008 May; 28(5):646-55. PubMed ID: 18447661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ranirestat has a stronger inhibitory activity on aldose reductase and suppresses inflammatory reactions in high glucose-exposed endothelial cells.
    Ishibashi Y; Matsui T; Matsumoto T; Kato H; Yamagishi S
    Diab Vasc Dis Res; 2016 Jul; 13(4):312-5. PubMed ID: 27190083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epalrestat, an aldose reductase ihibitor, reduces the levels of Nepsilon-(carboxymethyl)lysine protein adducts and their precursors in erythrocytes from diabetic patients.
    Hamada Y; Nakamura J; Naruse K; Komori T; Kato K; Kasuya Y; Nagai R; Horiuchi S; Hotta N
    Diabetes Care; 2000 Oct; 23(10):1539-44. PubMed ID: 11023149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.